uniQure (NASDAQ:QURE) Trading Down 3.3%

Shares of uniQure (NASDAQ:QURE – Get Rating) dropped 3.3% on Friday . The company traded as low as $20.86 and last traded at $20.88. Approximately 176,991 shares were traded during trading, a decline of 67% from the average daily volume of 543,980 shares. The stock had previously closed at $21.60.

Wall Street Analyst Weigh In

QURE has been the topic of a number of research analyst reports. The Goldman Sachs Group boosted their price target on uniQure from $47.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, November 23rd. Guggenheim restated a “buy” rating and set a $53.00 price target on shares of uniQure in a research note on Tuesday, February 28th. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of uniQure in a research report on Tuesday, February 28th. StockNews.com upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Credit Suisse Group upped their target price on uniQure from $51.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday, February 28th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.88.

uniQure Trading Down 1.9 %

The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.20 and a current ratio of 6.28. The firm has a market capitalization of $995.51 million, a price-to-earnings ratio of -7.82 and a beta of 1.19. The company has a 50 day moving average price of $21.64 and a two-hundred day moving average price of $21.11.

uniQure (NASDAQ:QURE – Get Rating) last announced its earnings results on Monday, February 27th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.89) by $1.04. The business had revenue of $102.75 million during the quarter, compared to the consensus estimate of $55.37 million. uniQure had a negative return on equity of 26.28% and a negative net margin of 119.07%. On average, research analysts forecast that uniQure will post -3.09 EPS for the current year.

Insider Transactions at uniQure

In related news, COO Pierre Caloz sold 2,941 shares of the stock in a transaction on Friday, December 9th. The stock was sold at an average price of $22.22, for a total value of $65,349.02. Following the completion of the transaction, the chief operating officer now directly owns 68,870 shares of the company’s stock, valued at approximately $1,530,291.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other uniQure news, insider Ricardo Dolmetsch sold 2,219 shares of the company’s stock in a transaction on Friday, December 9th. The stock was sold at an average price of $22.30, for a total value of $49,483.70. Following the completion of the sale, the insider now directly owns 127,406 shares in the company, valued at approximately $2,841,153.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Pierre Caloz sold 2,941 shares of the company’s stock in a transaction on Friday, December 9th. The shares were sold at an average price of $22.22, for a total value of $65,349.02. Following the completion of the sale, the chief operating officer now owns 68,870 shares of the company’s stock, valued at $1,530,291.40. The disclosure for this sale can be found here. Insiders sold a total of 25,754 shares of company stock valued at $580,424 in the last three months. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of uniQure

Several large investors have recently added to or reduced their stakes in QURE. Captrust Financial Advisors grew its holdings in shares of uniQure by 1,392.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 1,810 shares during the period. US Bancorp DE grew its holdings in shares of uniQure by 108.2% during the 2nd quarter. US Bancorp DE now owns 1,978 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,028 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of uniQure by 152.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,231 shares during the period. Covestor Ltd purchased a new position in shares of uniQure during the 1st quarter worth $50,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of uniQure by 128.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,457 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 1,944 shares during the period. 88.03% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

(Get Rating)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.